, Feb. 5, 2014
/PRNewswire/ -- Egalet Corporation ("Egalet") today announced the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $12.00
per share. All of the shares of common stock are being offered by Egalet. In addition, Egalet has granted the underwriters a 30-day option to purchase up to an additional 630,000 shares of common stock at the public offering price to cover over-allotments, if any. Separately, in a concurrent, side-by-side private placement, Egalet's collaborator Shionogi Limited has agreed to purchase 1,250,000 shares of common stock from Egalet at the public offering price. The company's shares are expected to begin trading on The NASDAQ Market on February 6, 2014
under the ticker symbol "EGLT." The offering is expected to close on February 11, 2014
, subject to customary closing conditions.
Stifel and JMP Securities are acting as joint book-running managers for the offering. Canaccord Genuity and Janney Montgomery Scott are acting as co-managers. A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on February 5, 2014. When available, copies of the final prospectus may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by calling (415) 364-2720 or by emailing SyndicateOps@stifel.com, or JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, California 94111, Attention: Prospectus Department, (415) 835-8985. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
Egalet Corporation is a specialty pharmaceutical company developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and other indications. The company has created two distinct drug delivery systems, each with novel abuse-deterrent features and the ability to control the release profile of the active pharmaceutical ingredient. Using its proprietary platform, Egalet has developed a pipeline of clinical-stage, opioid-based product candidates in tablet form that are specifically designed to deter abuse by physical and chemical manipulation, while also providing tailored release of the active pharmaceutical ingredient. Our lead product candidate, Egalet-001, is an abuse-deterrent, extended-release, oral morphine formulation in development for the treatment of moderate to severe pain. There are currently no commercially available abuse-deterrent formulations of morphine, and we believe that Egalet-001, if approved, would fill a significant unmet need in the marketplace. Our second product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation in development for the treatment of moderate to severe pain. The Egalet technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple APIs with similar or different release profiles. Visit www.egalet.com for more information.
Lisa M. Wilson
In-Site Communications, Inc.
E. Blair Clark-Schoeb
SOURCE Egalet Corporation